“These medications are saving lives,” said Anubha Agarwal, MD, assistant professor of medicine of cardiology and co-director of the program in global cardiovascular health at WashU Medicine in St. Louis. “There is not a financial incentive to produce them, which is an issue in high-income countries like the US and the UK.” The post Barriers Remain to Widespread Use of Polypills for CVD Therapy in High-Income Nations As Testing Continues appeared first on Cardiovascular Division.
